Incyte (INCY) – Hot FDA News
-
Syndax Pharmaceuticals (SNDX) Climbs 14% Following Positive Results form Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
-
Incyte (INCY) Phase 3 Trial Evaluating Ruxolitinib Cream in Children with Atopic Dermatitis Met Its Primary Endpoint
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to INCY Stock Lookup